Rajesh Jhorawat

Dr. Rajesh Jhorawat


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2016 in Indian Journal of Medical Research
Verified
Journal Article
Open access
PDF file
RJRajesh Jhorawat
Rajesh Jhorawat
SKSavita Kumari
Savita Kumari
SVSubhash C. Varma
Subhash C. Varma
MRManoj K. Rohit
Manoj K. Rohit
NNNidhi Narula
Nidhi Narula
SJSanjay K. Jain
Sanjay K. Jain
Background & objectives: Adriamycin though considered as an effective anticancer drug, leads to irreversible cardiomyopathy (CMP) and congestive heart failure (CHF). The aim of this study was to determine the protective effect of carvedilol in adriamycin (ADR)-induced cardiomyopathy (CMP) in cancer patients. Methods: Patients with lymphoreticular malignancy in whom ADR therapy was planned were randomized into two groups: carvedilol and control. Twenty seven patients each were enrolled in carvedilol and control groups. In the carvedilol group, 12.5 mg once daily oral carvedilol was given during six months. The patients were evaluated by echocardiography before and after chemotherapy. Left ventricular ejection fraction (EF) and systolic and diastolic diameters were calculated. Results: At six months of follow up, six patients in the carvedilol group and five in the control group had died. The mean EF (63.19 vs. 63.88%) and fraction shortening (FS) (34 vs. 34.6) of the carvedilol group were similar at follow up, but in the control group, the mean EF (67.27 vs. 60.82%, P=0.003) and FS (38.48 vs. 34.6, P<0.05) at control echocardiography were significantly lower. In carvedilol group, both systolic and diastolic diameters were not changed, but in control group, systolic diameters were significantly increased compared with basal measures (left ventricular end systolic diameter = 28.26±5.50 mm vs. 31.25± 6.50 mm; P< 0.05). Interpretation & conclusions: Prophylactic use of carvedilol in patients receiving anthracycline protected systolic functions of the left ventricle. Carvedilol can be a potential drug which can ameliorate ADR-induced CMP.

11 March 2025 in Kidney360
Verified
Journal Article
Open access
UCUttayan Chakrabarti
Uttayan Chakrabarti
RJRajesh Jhorawat
Rajesh Jhorawat
NBNitin Kumar Bajpai
Nitin Kumar Bajpai
ANAasma Nalwa
Aasma Nalwa
TDTapabrata Das
Tapabrata Das
MCManish Chaturvedy
Manish Chaturvedy
Key Points: Desmopressin is used to reduce bleeding complications in patients with qualitative and quantitative defects in platelet function. Bleeding complications were similar between the two groups. At 24 hours postbiopsy, desmopressin had more hematoma resolution than the control. The evaluation of hematoma in two time frames, 6 and 24 hours, assesses prolonged effect of desmopressin on bleeding complications. Background: Bleeding complications after a kidney biopsy are common in patients with a reduced kidney function. We performed a double-blinded, randomized controlled trial to examine the effect of desmopressin on bleeding complications after a kidney biopsy in patients with an eGFR ≤60 ml/min per 1.73 m2. Methods: We enrolled 152 patients (mean age, 39±15 years; 51% men), of whom 74 were randomized to an interventional group (intranasal desmopressin at 3 mcg/kg 1 hour before the biopsy) and 78 to a control group (intranasal saline). The primary study outcome was the overall frequency of bleeding complications. The secondary outcome was the size of the perinephric hematoma at 6 and 24 hours, assessed by a standardized ultrasound. Results: The baseline characteristics of the two treatment groups were well balanced. Overall, bleeding complications occurred in 64 of 152 (42%) of the study cohort, with 27 of 74 (36%) observed in the desmopressin group and 37 of 78 (47%) in the control group (risk ratio, 0.77; 95% confidence interval, 0.52 to 1.13; P = 0.17). The median hematoma size was similar in both groups at 6 hours (1.5 versus 2.7 ml, P = 0.34) and at 24 hours (1.2 versus 2.0 ml, P = 0.70). The frequency of a perinephric hematoma was similar in the desmopressin and placebo groups at 6 hours (35% versus 46%, P = 0.17), but lower in the desmopressin group at 24 hours (19% versus 36%, P = 0.02). Among the major bleeding complications, the frequency of blood transfusion (8.1% versus 6.4%, P = 0.69) and embolization (2.7% versus 1.3%, P = 0.61) was similar between the two groups. Conclusions: In patients with a reduced kidney function, the administration of desmopressin before a kidney biopsy does not reduce the frequency of bleeding complications or the postbiopsy perinephric hematoma volume at 6 or 24 hours.

1 January 2016 in Indian Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
RJRajesh Jhorawat
Rajesh Jhorawat
SJShailendra Jain
Shailendra Jain
APAjay Pal
Ajay Pal
SNSandeep Nijhawan
Sandeep Nijhawan
PBPankaj Beniwal
Pankaj Beniwal
VMVinay Malhotra
Vinay Malhotra

1 January 2015 in Tropical Parasitology
Verified
Journal Article
Open access
PDF file
RJRajesh Jhorawat
Rajesh Jhorawat
PBPankaj Beniwal
Pankaj Beniwal
VMVinay Malhotra
Vinay Malhotra
We are reporting a case of hemolytic uremic syndrome, a rare manifestation of Plasmodium vivax malaria. A young driver was admitted with acute febrile illness, decreased urine output, anemia, thrombocytopenia, jaundice, and increased serum lactate dehydrogenase. He showed a partial response to antimalarial drugs. However, he was readmitted with worsening renal parameters. His kidney biopsy revealed chronic thrombotic microangiopathy. He remained dialysis dependent and later underwent renal transplantation successfully, with excellent graft function at 1-year.

8 February 2024 in Indian Journal of Medical Sciences
Verified
Journal Article
Open access
RJRajesh Jhorawat
Rajesh Jhorawat
RMRavi Kumar Meena
Ravi Kumar Meena
SKSeetaram Singh Kularaj
Seetaram Singh Kularaj
SSSanjeev Kumar Sharma
Sanjeev Kumar Sharma
PBPankaj Beniwal
Pankaj Beniwal
VMVinay Malhotra
Vinay Malhotra
Objectives: Chronic kidney disease (CKD) is widely recognized as the leading cause of death worldwide. Diabetes and hypertension are common risk factors. This is the only study on CKD from Rajasthan that highlights basic CKD profiles in patients attending public tertiary care centers. Materials and Methods: This observation study included diagnosed cases of CKD attending nephrology outpatient department (OPD) from January to December 2020. Data regarding the cause of CKD, its stage, mode of renal replacement therapy (RRT), and direct cost of medication were collected. The state runs various schemes, including free dialysis facilities for all, below-poverty level cards (below poverty line [BPL] cards, which had complete free treatment), and state health cards Bhamasha Swasthya Bima Yojana (BSSY) under the government scheme. Results: A total of 252 patients were included in the study. Patients on dialysis were highest, followed by stage V and stage IV CKD, representing 33.73%, 18.65%, and 17.86%, respectively. Hypertension was the predominant cause of CKD, representing 29.37% and CKD (u) prevalence in our study was 14.68%. The direct cost of treatment at CKD stages I, II, III, IV, and V were Rs. 520 ($6.93), Rs. 2435.71 ($32.48), Rs. 3400 ($45.33), Rs. 3405.57 ($45.41), and Rs. 4815.97 ($64.21) per month, respectively. The monthly medicine cost of treatment on hemodialysis was Rs. 6730.60 ($89.74), Rs. 30,278 ($403.71) on peritoneal dialysis, and Rs. 5021.74 ($66.96) on renal transplant. BPL card holders were 8.33%, 39.68% had BSSY card, 16.27% had Insurance, and around one-third (35.71%) were without support. Conclusion: Age, socioeconomic status, and geographical location affect CKD etiology. The accessible dialysis facility, insurance, and government policies affect the selection of the RRT.

14 July 2023 in OBM Transplantation
Verified
Journal Article
Open access
PDF file
UCUttayan Chakrabarti
Uttayan Chakrabarti
MCManish Chaturvedy
Manish Chaturvedy
NBNitin Kumar Bajpai
Nitin Kumar Bajpai
JGJitendra Goswami
Jitendra Goswami
RGRajesh Kumar Garsa
Rajesh Kumar Garsa
RJRajesh Jhorawat
Rajesh Jhorawat
BK virus (BKV) is a common opportunistic pathogen in kidney transplant recipients and one of the most challenging causes of allograft dysfunction and loss. Although over-immunosuppression remains the primary risk factor for BKV infection after transplantation, male gender, older recipient age, prior rejection episodes, degree of human leukocyte antigen mismatching, prolonged cold ischemia time, BK virus serostatus and ureteral stent placement have all been implicated as risk factors. Routine screening post-renal transplant is important to prevent allograft loss in patients with BK viruria or viremia. Reduction of immunosuppression remains the mainstay of BKV nephropathy treatment and is the most studied intervention. In this review, we are going to discuss the epidemiology of BK virus infection, screening strategies, treatment options and new studies or evidence in the future.